The Global Business Development division of the Colorado Office of Economic Development and International Trade (OEDIT) announced today that TrAMPoline Pharma, Inc. was approved to receive a $500,000 Collaborative Infrastructure Grant through the Advanced Industries Accelerator Program.
The Collaborative Infrastructure Grant provides funding for collaborative projects that build infrastructure to fill gaps for the advanced industries in Colorado. Projects must have multiple collaborative public-private partners, broad impacts across one or more advanced industries, and support capability growth within the identified industries through research, technology development, and manufacturing.
TrAMPoline Pharma, in partnership with the Gates Biomanufacturing Facility at the University of Colorado Anschutz Medical Campus, is developing a centralized Colorado-based cellular immunotherapy manufacturing center to generate tumor-infiltrating lymphocytes (TIL) for the treatment of solid tumor cancers. This single universal process will generate a more effective TIL product and will be the first FDA-approved cellular immunotherapy and process for solid tumors in Colorado.
The AIA Program received two applications for this grant opportunity. Applications were reviewed by a multi-disciplinary committee of business, technical and financial experts in the seven advanced industries. Final recommendations were approved by the Economic Development Commission on June 15, 2023.